SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as discussions revolve around a boosted price target from an analyst, potentially signaling further upward momentum, while others point to declining sales figures and expiring EV subsidies, suggesting a possible downturn. The community is actively debating Tesla's financial health, delivery reports, and Elon Musk's strategic moves amid evolving competition in the EV sector. Broader market factors and technical levels are also being closely watched for potential directional shifts.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its recent listing on Bifinance and anticipates upcoming utility releases. Active community members highlight the coin's resilience and ongoing development efforts, emphasizing a grind mentality. Discussions also mention a watcher count milestone that could trigger a token burn.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending amid reports of potential investments or partnerships with TSMC and Apple, fueling speculation about its comeback in the semiconductor market. The community is actively discussing the implications of these developments, viewing them as a potential catalyst for growth. Broader discussions involve the company's role in the evolving tech ecosystem and government support for domestic chip manufacturing.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining ($CIFR) is trending due to a newly announced offering and a multi-billion dollar AI compute deal, sparking mixed reactions in the community. While some investors express concern over potential dilution from the offering, others view the deal with Google-backed Fluidstack as a major catalyst for growth in the AI data center space. Discussions also involve comparing $CIFR to peers like $IREN and analyzing potential price movements based on technical indicators and market sentiment.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

Iris Energy Ltd

Iris Energy (IREN) is trending as analysts boost price targets, citing the company's shift toward AI cloud services and strong execution. Community members are actively debating the stock's valuation and potential for further growth, with some pointing to the company's power capacity and AI infrastructure buildout. Recent discussions also highlight overnight price drops possibly due to market manipulation.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending due to a mix of factors, including positive trial data for their Alzheimer's treatment and GLP-1 pill, potentially impacting its competition with Novo Nordisk. Community discussions revolve around the implications of new U.S. manufacturing plants in light of potential tariffs, as well as debate over the efficacy and side effects of different weight loss drugs in the sector.

Pupu is a community-driven meme project centered around the character “Pupu the Frog,” who represents lighthearted fun and adventure within the crypto space. The project aims to build a digital ecosystem where holders can engage with the narrative of Pupu through memes, social interactions, and community activities. At its core, the project highlights creativity, entertainment, and community participation as primary utilities, while maintaining a transparent and decentralized structure that evolves through user engagement.

Pupu

$PUPU.X is trending as the community compares it to $PEPE, suggesting it could be the next big meme coin, particularly within the Solana ecosystem. Traders are highlighting bullish chart patterns and increased buying activity, with many emphasizing the ease of access through Phantom Wallet. The conversation is centered around the potential for a significant breakout and 'moon mission'.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The 'crow with knife' ($CAW.X) meme coin is gaining attention, with community members emphasizing its strong community and organic growth. Discussions highlight its presence across multiple chains like $SOL.X, $CRO.X, and $ETH.X, with a built-in burn mechanism that reduces supply over time.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQQF is trending due to anticipation surrounding its upcoming Nasdaq uplisting, with the community discussing potential impacts on price and institutional investment. Some traders are expressing concerns about possible dilution following the uplist, drawing parallels to a similar situation with DEFT. Bullish sentiment remains, driven by the company's focus on quantum-safe cryptography and endorsements of their QSSN technology.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI.X is trending as community members express strong conviction and excitement, using the term "WAGMI" (We Are All Gonna Make It) to foster a sense of unity. Discussions revolve around the token's potential for significant growth, its strong community, and its role within the broader meme coin cycle, particularly on the Solana blockchain and Pump.fun platform. Some users are highlighting the token's branding and positive messaging, suggesting it could be the next breakout narrative in the meme coin space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why JAZZ Stock Is an Unconventional Cannabis Investment

Jazz Pharma is redefining cannabis investing with Epidiolex, a fast-growing FDA-approved epilepsy drug fueling its growth.

Axsome Shares Up 20% in a Month: How Should You Play the Stock?

AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.

JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug

Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.

Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock

Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Jazz Pharmaceuticals experienced increased retail chatter on Wednesday after the U.S. Food and Drug Administration (FDA) granted accelerated approval to Modeyso (dordaviprone)&nbsp;for the treatment of a specific form of brain tumor.The drug is approved to treat adult and pediatric patients aged one year and older with diffuse midline glioma carrying an H3 K27M mutation, following progression after prior therapy. Continued approval may depend on confirmatory results from the Phase 3 ACTION trial.Modeyso is the first FDA-approved therapy for this rare and aggressive brain tumor, which affects an estimated 2,000 people in the U.S. annually, many of them children and young adults, according to the company.The oral, once-weekly capsule is expected to be commercially available in the coming weeks. The FDA based its decision on data from 50 patients enrolled across five open-label studies. About 1 in 5 patients responded to treatment, with responses lasting a median of just over 10 months.&nbsp;Among those who responded, nearly three-quarters saw benefits for at least six months, and more than a quarter maintained their response for at least a year.Patrick Wen of Dana-Farber Cancer Institute called the approval a “major turning point in neuro-oncology,” noting that Modeyso introduces a new treatment option for a population with limited choices.&nbsp;About a third of glioma patients in the trial experienced serious side effects on Modeyso, including hydrocephalus, seizures, vomiting, and muscle weakness. Fatigue, nausea, and headaches were the most common complaints.Separately, Truist Securities reduced its price target on Jazz Pharmaceuticals to $200 from $230, citing slower momentum in Epidiolex and cancer therapies such as Rylaze and Zepzelca.&nbsp;In the second quarter, Rylaze revenue dropped 7% to $100.7 million, and Zepzelca sales slipped 8% to $74.5 million. Epidiolex posted modest 2% growth to $251.7 million.&nbsp;Truist noted that the company’s total revenue was propped up by strong momentum in the oxybate franchise, where the lead drug, Xywav, rose 13% to $415.3 million. However, it flagged potential headwinds from two upcoming non-oxybate narcolepsy treatments nearing FDA review.On Stocktwits, retail sentiment for Jazz Pharmaceuticals was ‘extremely bullish’ amid ‘high’ message volume.<a href="https://stocktwits.com/symbol/JAZZ">Jazz Pharmaceuticals’ stock</a> has declined 14.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Jazz Pharmaceuticals (JAZZ) experienced increased retail chatter on Wednesday after the U.S. Food and Drug Administration (FDA) granted accelerated approval to Modeyso  (Photo credit: Getty Images)

Retail Traders Cheer Jazz Pharma After FDA Clears Rare Drug For Brain Tumor

The approval was based on pooled data from 50 patients in five open-label trials, showing an overall response rate of 22%, with a median response duration of 10.3 months.

Equity

JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut

Jazz shares slide as Q2 loss widens on Chimerix charge, with 2025 sales outlook trimmed despite higher EPS guidance.

Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of -34.80% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.

Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

Current Price	$127.80
Prev Close	$129.59
Open	$128.99
Dividend Yield	0.00%
50-Day Moving Average	$121.38
Beta	0.74
Avg. Volume	889,998.05
PE Ratio	-18.94

52-Week High	$148.06
52-Week Low	$95.49
Market Capitalization	$7.75B
EPS (Annual)	$8.65
Price to Book	2.09
Revenue Per Employee	$1.45M
Enterprise Value/EBITDA	N/A

JAZZ
Jazz Pharmaceuticals plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JAZZ News

JAZZ Jazz Pharmaceuticals plc